2016年乳腺癌治疗的3大突破

2016-10-25 风云/新康界 风云/新康界

在美国,八分之一的女性一生中将被诊断出乳腺癌。十年前,我成为了其中一名,忍受着化疗、手术、放疗,以及随后的脱发和持续性恶心。但现在对于所有女性有重大的消息。这些有毒性的治疗方案可能会被遗弃,因为乳腺癌的治疗正在迅速转向更加个性化和针对性,这可以挽救数百万人的生命,并彻底改变患者的生活质量。三大突破将产生更有效的治疗以及重新思考致病的原因。靶向联合治疗完全消除癌症迹象2016年乳腺癌治疗最大的进步是



在美国,八分之一的女性一生中将被诊断出乳腺癌。十年前,我成为了其中一名,忍受着化疗、手术、放疗,以及随后的脱发和持续性恶心。但现在对于所有女性有重大的消息。这些有毒性的治疗方案可能会被遗弃,因为乳腺癌的治疗正在迅速转向更加个性化和针对性,这可以挽救数百万人的生命,并彻底改变患者的生活质量。三大突破将产生更有效的治疗以及重新思考致病的原因。

靶向联合治疗完全消除癌症迹象

2016年乳腺癌治疗最大的进步是癌症靶向的药物联合如何在11天内使11%的患者完全没有乳腺癌迹象。这项英国研究涉及257例HER2阳性乳腺癌,并联合两种药物分别来自GlaxoSmithKline(葛兰素史克公司)(NYSE:GSK) 和 Roche Holdings(罗氏制药) (NASDAQOTH:RHHBY)。

11%也许看起来不够令人振奋,但是药物不到两个星期就将乳腺癌肿瘤完全根除,这是令人疯狂的。肿瘤对化疗药物产生耐药性非常迅速,甚至大约几个月的治疗后就没什么效果。相反,我们先手术切除肿瘤,然后化疗从而清除可能扩散到身体其他地方的肿瘤细胞。

在过去的几年里,只有小部分妇女首先接受化疗。尽管方案有时能缩小肿瘤,但是治疗的顺序是相反的。因为肿瘤专家更关心的是癌症转移位置,而不是原发肿瘤。但Glaxo(葛兰素史克)和Roche(罗氏)的药物Herceptin和Tykerb -不是静脉注射化疗药物,而是简单的口服药。此外,这些药物是高度靶向治疗,并专门攻击癌细胞。这是一个巨大的加分项,因为患者不必面临化疗的严重副作用,如杀死身体中的所有快速分裂的细胞,如毛囊和健康的骨髓细胞。

更好的是,市场上已经有很多新型疗法,包括单克隆抗体如Herceptin和Tykerb,检查点产品如PD-1和其他激发病人免疫系统的治疗方法。正如在Glaxo/Roche的药物试验,将这些药物二合一能提高治疗成功的概率,最终可能治愈。

确定乳腺癌的93个致病基因

今年5月,英国剑桥研究所的研究人员解开了乳腺癌致病基因的全貌。由于他们的努力,我们很快就会知道为什么特定人群会发病。

具体来说,科学家们发现了93个基因,这些基因的突变将一个正常的乳腺细胞转化成癌细胞。Mike Straton教授声称,这份名单将移交给大学,制药企业,生物科技公司,从而开发新的药物。我们对癌症的遗传学了解越多,我们就越知道什么样的治疗方法对于特定人群有效,从而提高患者生存率。

血液测试可以代替代乳房X光

今年的巨大突破使我们开始接触乳腺癌血液测试。具体地说,法国和澳大利亚的研究人员报道称,碳、氮同位素比例的变化可以揭示疾病的存在。

随着这种新型检测乳腺癌的方法,该项目的首席研究员Guillaume Tcherkez教授说,我们几年后会有简单的血液测试。对于女性来说,这是个好消息,因为目前最好用的乳房X光检查,有16%不准确率。误诊结果包括假阳性(屏幕不正确显示乳房)和假阴性(无法检测肿瘤)。

一项新型的乳腺癌血液测试在法国正在开发。而美国的基因测序巨头Illumina公司(NASDAQ:ILMN)正致力于一体化液体癌活检,从而检测几乎所有的癌症。Illumina公司声称早期版本会在三年后进入市场。如果这一目标实现,许多形式的癌症将被提前发现,在它还可以治疗的时候,这应该大规模降低世界的癌症死亡率。

如何利用乳腺癌突破治疗肿瘤

可能患有乳腺癌的人,其中包括所有的女性以及所有的男性(尽管很少)都将受益于乳腺癌的突破性进展。疾病侵袭悄无声息,随着新型疗法涌入市场,许多医生从来开过这些药物,可能会犹豫,甚至怀疑他们可能的好处。

事实上,保护自己的健康是战胜这种疾病的最好方法。但这并不意味着你可以忽略你的医生的建议,你应该努力预防癌症,如健康饮食和锻炼,确保你得到必要的检查,如果诊断为癌症,询问问题,如果你对答案不满意,寻求第二家意见。虽然在过去的20年中,生存率增加了一倍,但在美国,每12分钟就有一个妇女死于乳腺癌。所以永远不要忘记,这种疾病给你的生活带来了严重的威胁,没有人比你更关心你的生活了。

但是也没必要悲伤,因为现在研究显示我们自己的身体可以充分地激活来战斗。这不仅提高了生存的可能性,它也使我们更接近治愈乳腺癌的那天。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=155861, encodeId=c24a155861a3, content=靶向治疗科学前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:11:11 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155860, encodeId=4d54155860cd, content=关爱自己,珍惜生命, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:10:14 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155859, encodeId=3621155859a0, content=增强信心,生活更美好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:09:34 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155858, encodeId=d94515585813, content=很好,真的实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:08:41 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151454, encodeId=05d0151454a0, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Oct 27 08:32:28 CST 2016, time=2016-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151282, encodeId=0d151512823c, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a261955276, createdName=1e1230cem08(暂无匿称), createdTime=Wed Oct 26 08:43:37 CST 2016, time=2016-10-26, status=1, ipAttribution=)]
    2016-11-15 往日如昨

    靶向治疗科学前沿

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=155861, encodeId=c24a155861a3, content=靶向治疗科学前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:11:11 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155860, encodeId=4d54155860cd, content=关爱自己,珍惜生命, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:10:14 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155859, encodeId=3621155859a0, content=增强信心,生活更美好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:09:34 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155858, encodeId=d94515585813, content=很好,真的实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:08:41 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151454, encodeId=05d0151454a0, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Oct 27 08:32:28 CST 2016, time=2016-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151282, encodeId=0d151512823c, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a261955276, createdName=1e1230cem08(暂无匿称), createdTime=Wed Oct 26 08:43:37 CST 2016, time=2016-10-26, status=1, ipAttribution=)]
    2016-11-15 往日如昨

    关爱自己,珍惜生命

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=155861, encodeId=c24a155861a3, content=靶向治疗科学前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:11:11 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155860, encodeId=4d54155860cd, content=关爱自己,珍惜生命, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:10:14 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155859, encodeId=3621155859a0, content=增强信心,生活更美好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:09:34 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155858, encodeId=d94515585813, content=很好,真的实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:08:41 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151454, encodeId=05d0151454a0, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Oct 27 08:32:28 CST 2016, time=2016-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151282, encodeId=0d151512823c, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a261955276, createdName=1e1230cem08(暂无匿称), createdTime=Wed Oct 26 08:43:37 CST 2016, time=2016-10-26, status=1, ipAttribution=)]
    2016-11-15 往日如昨

    增强信心,生活更美好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=155861, encodeId=c24a155861a3, content=靶向治疗科学前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:11:11 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155860, encodeId=4d54155860cd, content=关爱自己,珍惜生命, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:10:14 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155859, encodeId=3621155859a0, content=增强信心,生活更美好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:09:34 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155858, encodeId=d94515585813, content=很好,真的实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:08:41 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151454, encodeId=05d0151454a0, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Oct 27 08:32:28 CST 2016, time=2016-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151282, encodeId=0d151512823c, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a261955276, createdName=1e1230cem08(暂无匿称), createdTime=Wed Oct 26 08:43:37 CST 2016, time=2016-10-26, status=1, ipAttribution=)]
    2016-11-15 往日如昨

    很好,真的实用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=155861, encodeId=c24a155861a3, content=靶向治疗科学前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:11:11 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155860, encodeId=4d54155860cd, content=关爱自己,珍惜生命, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:10:14 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155859, encodeId=3621155859a0, content=增强信心,生活更美好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:09:34 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155858, encodeId=d94515585813, content=很好,真的实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:08:41 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151454, encodeId=05d0151454a0, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Oct 27 08:32:28 CST 2016, time=2016-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151282, encodeId=0d151512823c, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a261955276, createdName=1e1230cem08(暂无匿称), createdTime=Wed Oct 26 08:43:37 CST 2016, time=2016-10-26, status=1, ipAttribution=)]
    2016-10-27 李东泽

    很好,不错,以后会多学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=155861, encodeId=c24a155861a3, content=靶向治疗科学前沿, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:11:11 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155860, encodeId=4d54155860cd, content=关爱自己,珍惜生命, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:10:14 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155859, encodeId=3621155859a0, content=增强信心,生活更美好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:09:34 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155858, encodeId=d94515585813, content=很好,真的实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Tue Nov 15 11:08:41 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151454, encodeId=05d0151454a0, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Oct 27 08:32:28 CST 2016, time=2016-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151282, encodeId=0d151512823c, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a261955276, createdName=1e1230cem08(暂无匿称), createdTime=Wed Oct 26 08:43:37 CST 2016, time=2016-10-26, status=1, ipAttribution=)]
    2016-10-26 1e1230cem08(暂无匿称)

    不错不错

    0

相关资讯

倒夜班可以增加患乳腺癌风险?

根据一份新的分析表明,夜班,包括长期倒班工作,对女性发展成为乳腺癌的风险“很小或没有”。但是最新的研究否定了之前诸多的结论,并称二者有关系。三位专家为这项最新的研究打起口水战,声称其结论漏洞百出。 调查结果是通过对英国三个大型前瞻性研究得出的,其中包括约 800,000 名女性和 10组对1,400,000 名女性的Meta 分析。 这三项研究,发现夜班工作,包括长期夜班工作与患乳腺癌没有

BMJ:胰高血糖素样肽-1类似物不会增加乳腺癌风险

来自加拿大的研究人员开展了一项基于人群的队列研究。

收藏!美国三大学会联合发布乳癌术后放射治疗新指南

三大学会联合发布乳癌术后放射治疗指南,建议收藏~美国临床肿瘤学会(ASCO)、美国放射肿瘤学会(ASTRO)和肿瘤外科学会在《临床肿瘤学杂志》上联合发布了乳癌全乳切除手术后放射治疗的新指南。 临床问题1:I期或II期乳癌全乳切除手术和腋窝淋巴结清扫后,有1到3个淋巴结转移,是否应该作放疗? 建议•1A:专家组一致认为,现有证据表明,乳癌全乳切除手术后放射治疗可以减少那些有1到3

Br J Cancer:乳腺癌病史会导致更差的卵巢癌结局?

乳腺癌病史是否会影响BRCA1/2相关的上皮性卵巢癌患者的结局,目前仍不清楚。基于此,进行了本项研究。 我们纳入了386例BRCA1/2相关的上皮性卵巢癌患者,诊断时间为1980年到2015年。比较有乳腺癌病史和没有乳腺癌病史患者的无进展生存期(PFS)、无进展间隔期(PFI)、总生存期(OS)和卵巢癌特异生存率(OCSS)。 分析结果显示,BRCA1/2相关的上皮性卵巢癌患者,伴有乳

Cancer:研究表明精准医学进展能够改善乳腺癌治疗

最近一项研究展示了如何利用精准医学方法——肿瘤基因组检测——帮助乳腺癌患者减少过度治疗,将化疗的作用最大化。相关研究结果发表在国际学术期刊Cancer上。研究发现医生建议和最终治疗决策与病情检查结果高度相关,表明肿瘤基因组检测能够帮助医生辨别哪些病人能够从化疗中获益最大,哪些病人可以安全地停止化疗治疗。癌症领域的大多数精准医学研究都针对参与临床试验的病人。几乎没有研究对于医生如何利用生物标记物检测

盘点:近期乳腺癌重大研究汇总

乳腺癌是发生在乳腺腺上皮组织的恶性肿瘤。全球乳腺癌发病率自20世纪70年代末开始一直呈上升趋势;我国乳腺癌的发病率也逐年上升,每年有近20万女性被诊断出乳腺癌。从死亡率的曲线也可以看出,随着新的治疗策略和方法的普及,虽然全球乳腺癌的死亡率逐步下降,但中国乳腺癌死亡率的下降趋势不显著。本文梅斯医学小编就近期乳腺癌相关研究进行盘点。【1】NEJM:HR阳性HER2阴性的晚期乳腺癌,ribocicl